Single-Dose Crossover Comparative Bioavailability Study of Two Different Posaconazole 100 mg Gastro-Resistant Tablets Under Fasted and Fed Conditions in Healthy Volunteers

Nilden Dayan and others

Posaconazole is a systemic extended-spectrum triazole mainly licensed for prophylaxis of invasive fungal infections (IFIs) in high-risk patients. Three formulations of posaconazole are currently available, including an oral suspension (40 mg/mL), a delayed-release gastric-resistant (...) Read More